Literature DB >> 3085470

The immunochemical characterization of the light chains in the mesangial IgA deposits in IgA nephropathy.

K N Lai, K W Chan, F Mac-Moune, C P Ho, K W Yan, C W Lam, J Vallance-Owen.   

Abstract

The immunochemical characterization of the light chains of the mesangial immunoglobulin A (IgA) deposits were studied in 45 patients with IgA nephropathy. Kappa and lambda light chains were detected with direct immunofluorescence (IF) method, using monospecific rabbit anti-human anti-kappa and anti-lambda anti-sera. The glomeruli of 42 renal biopsies studied were strongly positive for lambda light chain, while only 25 specimens were positive for kappa light chain. Sixty-five percent of the biopsies showed a predominance of lambda light chain IF staining in the mesangial deposits. This IF pattern is unique as compared with similar studies on renal biopsies from patients with systemic lupus erythematosus, idiopathic membranous nephropathy, and normal postmortem renal tissue. The results indicate that mesangial IgA deposits in IgA nephropathy consist mainly of IgA with lambda light chains despite the fact that the normal ratio of kappa to lambda light-chain-containing immunoglobulin in human serum is two to one.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085470     DOI: 10.1093/ajcp/85.5.548

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  Clinicopathological significance of light chain deposition in IgA nephropathy.

Authors:  Ritsuko Katafuchi; Hiroshi Nagae; Kosuke Masutani; Toshiaki Nakano; Mikio Munakata; Kazuhiko Tsuruya; Koji Mitsuiki
Journal:  Clin Exp Nephrol       Date:  2021-03-01       Impact factor: 2.801

2.  Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy.

Authors:  Hiroshi Nagae; Akihiro Tsuchimoto; Kazuhiko Tsuruya; Shota Kawahara; Yukiko Shimomura; Hideko Noguchi; Kosuke Masutani; Ritsuko Katafuchi; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2016-05-12       Impact factor: 2.801

3.  The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.

Authors:  Shiren Sun; Wang Di; Rong Li; Xiaoxia Yang; Qin Jia; Chunmei Liu; Feng Ma
Journal:  Int Urol Nephrol       Date:  2021-11-18       Impact factor: 2.370

4.  Light-chain ratio of serum IgA1 in IgA nephropathy.

Authors:  S H Chui; C W Lam; W H Lewis; K N Lai
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

Review 5.  Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.

Authors:  J Mestecky; M Tomana; Z Moldoveanu; B A Julian; H Suzuki; K Matousovic; M B Renfrow; L Novak; R J Wyatt; J Novak
Journal:  Kidney Blood Press Res       Date:  2008-01-08       Impact factor: 2.687

Review 6.  Pathogenesis of idiopathic IgA nephropathy.

Authors:  D G Williams
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

7.  Immunofluorescence characterization of light chains in human nephropathies.

Authors:  C Orfila; J Rakotoarivony; Y Manuel; J M Suc
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  Clinicopathologic and Prognostic Study of Primary IgA Nephropathy With Light Chain λ Restriction in the Mesangial Deposits.

Authors:  Ji Zhang; Ziyuan Huang; Sishi Lin; Ya Hu; Yan Liang; Wenxian Qiu; Bo Chen; Chaosheng Chen
Journal:  Kidney Int Rep       Date:  2022-01-26

9.  Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.

Authors:  Katerina Zachova; Jana Jemelkova; Petr Kosztyu; Yukako Ohyama; Kazuo Takahashi; Josef Zadrazil; Jiri Orsag; Karel Matousovic; Dana Galuszkova; Nadezda Petejova; Jiri Mestecky; Milan Raska
Journal:  J Am Soc Nephrol       Date:  2022-02-03       Impact factor: 14.978

10.  Significance of subepithelial deposits in patients diagnosed with IgA nephropathy.

Authors:  Mineaki Kitamura; Yoko Obata; Yuki Ota; Kumiko Muta; Hiroshi Yamashita; Takashi Harada; Hiroshi Mukae; Tomoya Nishino
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.